Physician profile
Brian Delaney
NPI 1528081320
$657.11
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $98.55 · 2021: $191 · 2022: $49.76 · 2023: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $100.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $88.84 | 2019-2021 | |
| Novo Nordisk INC | $77.47 | 2019 | |
| Daiichi Sankyo INC. | $67.95 | 2021-2023 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $58.04 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $48.33 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $45.28 | 2021 | |
| Glaxosmithkline, LLC. | $29.66 | 2023 | Shingrix, Arexvy |
| Emd Serono, INC. | $28.56 | 2021 | |
| Shionogi INC | $25.83 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.50 | 2020 | |
| Acorda Therapeutics, INC | $23.92 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.17 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $23.15 | 2019 | |
| Gilead Sciences, INC. | $18.23 | 2021 | |
| Intra-Sana Laboratories | $17.47 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $14.96 | 2020 | |
| Amarin Pharma, INC. | $14.57 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.31 | 2019 | |
| Merck Sharp & Dohme LLC | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Delaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.